3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
2
Endocrine
2
Conditions
Breast Neoplasms
1931
Neoplasms
1385
Carcinoma, Non-Small-Cell Lung
1324
Prostatic Neoplasms
1070
Multiple Myeloma
855
Leukemia, Myeloid, Acute
759
Neoplasm Metastasis
691
Colorectal Neoplasms
676
Melanoma
666
Lung Neoplasms
665
Lymphoma
655
Leukemia
591
Lymphoma, Non-Hodgkin
587
Leukemia, Lymphocytic, Chronic, B-Cell
529
Ovarian Neoplasms
517
Pancreatic Neoplasms
493
Precursor Cell Lymphoblastic Leukemia-Lymphoma
471
Recurrence
466
Myelodysplastic Syndromes
421
Lymphoma, Follicular
407
Head and Neck Neoplasms
401
Glioblastoma
376
Carcinoma, Renal Cell
375
Lymphoma, Large B-Cell, Diffuse
372
Brain Neoplasms
370
Hodgkin Disease
352
Carcinoma, Hepatocellular
324
Squamous Cell Carcinoma of Head and Neck
323
Lymphoma, Mantle-Cell
302
Sarcoma
281
Interventions
vandetanib
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Has results
×
Differentiated Thyroid Cancer
×
Clear all
NCT01876784
2024-07-23
VERIFY
Sanofi
Phase 3
Completed
238 enrolled
12 charts
NCT01843062
2019-08-28
ASTRA
AstraZeneca
Phase 3
Terminated
233 enrolled
14 charts